Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer

Andrew Tutt(Institute of Cancer Research), Charles E. Geyer(Magee-Womens Hospital)

New England Journal of Medicine

June 3, 2021

10.1056/nejmoa2105215

Cited by 1,633

Related Papers

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

|The Lancet|2014|4.7k

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

|Annals of Oncology|2016|2.1k

Mutational Processes Molding the Genomes of 21 Breast Cancers

|Cell|2012|2k

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

|Annals of Oncology|2015|1.8k

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

|The Lancet|2010|1.6k